Currently, U.S. Food and Drug Administration (FDA)-approved STAT3 inhibitors primarily target the dimerization of STAT3 by binding to the STAT3 SH2 domain and are restricted to cancer therapy. This evidence concerns the gene STAT3 and cancer.